Ibnsina Pharma (CAI:ISPH) Interest Expense: E£-2,416 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI:ISPH Ibnsina Pharma CAI:ISPH
90 GF Score
Price E£11.53
GF Value E£10.59
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Ibnsina Pharma Interest Expense?

Ibnsina Pharma CAI:ISPH -0.95% 90 Interest Expense is E£-2,416 Mil as of Mar. 2026. GuruFocus rates CAI:ISPH with a GF Score™ of 90/100 and a GF Value™ of E£10.59 (Fairly Valued). The stock has 7 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Ibnsina Pharma's interest expense for the three months ended in Mar. 2026 was E£ -468 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was E£-2,416 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Ibnsina Pharma's Operating Income for the three months ended in Mar. 2026 was E£ 689 Mil. Ibnsina Pharma's Interest Expense for the three months ended in Mar. 2026 was E£ -468 Mil. Ibnsina Pharma's Interest Coverage for the quarter that ended in Mar. 2026 was 1.47. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ibnsina Pharma  (CAI:ISPH) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ibnsina Pharma's Interest Expense for the three months ended in Mar. 2026 was E£-468 Mil. Its Operating Income for the three months ended in Mar. 2026 was E£689 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was E£2,039 Mil.

Ibnsina Pharma's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*688.933/-468.493
=1.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Warning Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Ibnsina Pharma interest coverage is 1.46, which is low.

Ibnsina Pharma Interest Expense Historical Data

* Premium members only.

The historical data trend for Ibnsina Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ibnsina Pharma Interest Expense Chart

Ibnsina Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -284.18 -477.09 -1,043.96 -1,686.30 -2,558.62

Ibnsina Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -611.22 -691.87 -646.79 -608.74 -468.49
CAI:ISPH
90GF Score
Ibnsina Pharma CAI:ISPH
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ibnsina Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£-2,416 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of E£-2,416 Mil mean?
Ibnsina Pharma (CAI:ISPH) has a Interest Expense of E£-2,416 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Ibnsina Pharma and its competitors.
Is Ibnsina Pharma's Interest Expense too high?
Ibnsina Pharma's current Interest Expense is E£-2,416 Mil. Overall, Ibnsina Pharma has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's Interest Expense compare to MCK and COR?
Ibnsina Pharma's Interest Expense of E£-2,416 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Medical Distribution company?
A good Interest Expense depends on the Medical Distribution industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Ibnsina Pharma and its competitors. Ibnsina Pharma's current Interest Expense is E£-2,416 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Fairly Valued. The stock's GF Value™ is E£10.59, compared to a current price of E£11.53 — trading 8.9% above its estimated fair value. The current Interest Expense is E£-2,416 Mil. Ibnsina Pharma's overall GF Score™ is 90/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current Interest Expense is E£-2,416 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?

Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued. The current stock price of E£11.53 is trading 8.9% above its estimated GF Value™ of E£10.59. GuruFocus considers Ibnsina Pharma to be Fairly Valued.

Key valuation signals for CAI:ISPH:

  • Interest Expense: E£-2,416 Mil
  • GF Value™: E£10.59 vs. price of E£11.53 (8.9% above fair value)
  • GF Score™: 90/100 with 7 warning signs

No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ibnsina Pharma Business Description

Address Industrial zone 1, PO box 91, Obour, EGY
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
90GF Score

Get the complete analysis for CAI:ISPH

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£11.53
Price
E£10.59
GF Value